News & Updates

The use of fluvoxamine for outpatient treatment of mild-to-moderate COVID-19 falls short of reducing the duration of symptoms, as shown in the ACTIV-6 study.

In a preliminary analysis, the risk of severe outcomes was higher in individuals infected with the Omicron XBB.1.16 subvariant compared with those who were infected with other subvariants such as the XBB.1.5 or XBB.1.9.

The oral selective tyrosine kinase inhibitor sunvozertinib demonstrates therapeutic potential in patients with nonsmall cell lung cancer (NSCLC) with EGFR exon 20 insertions (exon20ins) who have previously received platinum-based chemotherapy, according to the results of a phase II WU-KONG6 study.

People with nocturnal gastroesophageal reflux (GER) and habitual snoring are vulnerable to developing asthma and respiratory symptoms, according to a study.

In the first-line treatment of locally advanced or metastatic nonsmall cell lung cancer (NSCLC) patients with EGFR exon 20 insertion (ex20ins) mutations, the investigational mobocertinib is safe and efficacious but not necessarily better than platinum-based chemotherapy, according to the phase III EXCLAIM-2 trial.

Coadministration of the BNT162b2 BA.4/5 bivalent mRNA COVID-19 vaccine (BNT162b2-biv) and the seasonal influenza vaccine (SIV) offers protection against the two infections, with an efficacy that is similar as when giving each vaccine alone, according to a study.